<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>866</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10477565</PubmedId>
            <Abstract>In vitro stimulation of mouse splenocytes with hemagglutinin (HA) 173-190, a peptide derived from influenza virus hemagglutinin (A/JAP/305/57, H2N2), induces CTLs that are directed to the MHC class Ib molecule, H2-M3. M3 preferably binds peptides bearing an N-terminal formylmethionine. In this study, we show that several related nonformylated peptides can induce anti-HA CTLs in vitro: MLIIW (the minimal epitope), derived from HA186-190 at the C-terminal end of HA173-190; MLIIWG; MLIIWGV; and MLIIWGI, as well as formylated MLIIW. The heptamer peptides correspond to a polymorphism of HA192 in H2 strains of influenza; they have the highest relative affinities for M3 of the nonformylated peptides and higher affinities than some formylated mitochondrial peptides. Depending on the affinity of the peptide, a range of concentrations can be used to induce CTLs. One nanomolar of the high affinity f-MLIIW peptide can induce anti-HA CTLs, whereas 100-fold more of the lower affinity MLIIW peptide is needed. Lines induced with high concentrations (1 microM or greater) of f-MLIIW recognize Ag poorly, and the most efficient CTLs are induced with the lowest concentrations of peptide. Analysis with a panel of anti-TCRVbeta Abs shows that different T cells respond to high vs low peptide; the repertoire of cells responding to higher concentrations is more diverse, consistent with the expansion of more, but less efficient, clones. Thus, peptide affinity and concentration should be considered together for generating efficient antipeptide CTLs in vitro.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>3022-8</ArticlePages>
            <ArticleTitle>Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Byers</LastName>
                    <ForeName>D E</ForeName>
                </Author>
                <Author>
                    <LastName>Lindahl</LastName>
                    <ForeName>K F</ForeName>
                </Author>
            </Authors>
            <Affiliations>Howard Hughes Medical Institute, Center for Immunology, University of Texas Southwestern Medical Center, Dallas 75235, USA.</Affiliations>
            <ArticleChemicalList>H2-M3 antigen;Hemagglutinin Glycoproteins, Influenza Virus;Histocompatibility Antigens Class I;Oligopeptides;Receptors, Antigen, T-Cell, alpha-beta</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antigen Presentation; Cell Line; Cytotoxicity, Immunologic; Dose-Response Relationship, Immunologic; Female; Hemagglutinin Glycoproteins, Influenza Virus(immunology); Histocompatibility Antigens Class I(immunology); Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred NZB; Molecular Sequence Data; Oligopeptides(immunology; metabolism); Protein Binding(immunology); Receptors, Antigen, T-Cell, alpha-beta(analysis; biosynthesis); T-Lymphocytes, Cytotoxic(immunology; metabolism; virology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>163</Volume>
                <Issue>6</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA186-190</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MLIIW</LinearSequence>
                        <StartingPosition>186</StartingPosition>
                        <EndingPosition>190</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3023</LocationOfData>
                <EpitopeId>41967</EpitopeId>
                <ReferenceStartingPosition>186</ReferenceStartingPosition>
                <ReferenceEndingPosition>190</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Sequence shown previously to be the minimal epitope recognized by CTLs induced with peptide HA173-190 (VAKGSYNNTSGEQMLIIW). In this paper, it is shown that heptamers with 2 extra C terminal aa (MLIIWGI or MLIIWGV) are better at sensitizing APCs. This is a M3 restricted epitope, albeit its affinity for this MHC molecule specialized in presentation of formylated peptides is ~100 fold lower than the formylated version of the peptide.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1 and 3</LocationOfData>
                        <TCellId>9500</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenReferenceName>HA 186-190</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MLIIW</LinearSequence>
                                            <StartingPosition>186</StartingPosition>
                                            <EndingPosition>190</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>NaÃÂ¯ve splenocytes from C57BL/6J mice were used to establish peptide specific CTLs  by weekly stimulation with syngeneic irradiated spleen cells pulsed with 1 μM peptide. 12 weeks of restimulation were necessary to obtain CTLs against this epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Plasma cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000639</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>128</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA186-190</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLIIW</LinearSequence>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>190</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide is able to sensitize APCs for recognition by anti-cognate CTLs at 1 μM but not at 1 nM concentration. The CTLs generated with lower concentrations of peptide are more sensitive than those obtained with higher concentrations, as they are able to lyse APCs sensitized with lower concentrations of both non-formylated or formylated peptide. Theplasmacitoma cell line Pc11198 were used as target cells to measure M3 restricted response since they are H2^d2 and therefore eliminate the chance for H2 or Qa1 restricted recognition and lysis by CTLs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure  2</LocationOfData>
                        <MhcBindingId>10479</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide was able to compete with the binding to M3 MHC molecules of formylated peptide MFFINVLTL, albeit weakly, requiring 10^4-fold higher concentration to inhibit 50% of binding.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>128</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA186-190</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MLIIW</LinearSequence>
                        <ModifiedResidues>M1</ModifiedResidues>
                        <Modifications>Formylation|FORM</Modifications>
                        <StartingPosition>186</StartingPosition>
                        <EndingPosition>190</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3023</LocationOfData>
                <EpitopeId>41966</EpitopeId>
                <ReferenceStartingPosition>186</ReferenceStartingPosition>
                <ReferenceEndingPosition>190</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Artificially formylated version of minimal epitope of M3 restricted anti-HA CTL response. Its affinity for M3 is ~100 fold higher than the nonformylated version of the peptide.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  3</LocationOfData>
                        <TCellId>9506</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenReferenceName>HA186-190</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MLIIW</LinearSequence>
                                            <ModifiedResidues>M1</ModifiedResidues>
                                            <Modifications>Formylation|FORM</Modifications>
                                            <StartingPosition>186</StartingPosition>
                                            <EndingPosition>190</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>NaÃÂ¯ve splenocytes from C57BL/6J mice were used to establish peptide specific CTLs  by weekly stimulation with syngeneic irradiated spleen cells pulsed with 0.01, 0.1 or 1 μM peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Plasma cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000639</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>128</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA186-190 M1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLIIW</LinearSequence>
                                        <ModifiedResidues>M1</ModifiedResidues>
                                        <Modifications>Formylation|FORM</Modifications>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>190</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide specific CTLs generated after 12 weeks of in vitro stimulation with 0.01 μM peptide were more sensitive than CTLs induced with 0.1 μM peptide, as they were able to lyse APCs sensitized with lower concentrations of both non-formylated or formylated peptide. CTLs failed to lyse cells pulsed with up to 1μM nonformylated peptide or 0.01μM epitope, implicating its reduced sensitivity. High and low concentration-induced lines were of different TCR V β germlines. The plasmacitoma cell line Pc11198 was used as target cells to measure M3 restricted response since they are H2^d2 and therefore eliminate the chance for H2 or Qa1 restricted recognition and lysis by CTLs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA186-191</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MLIIWG</LinearSequence>
                        <StartingPosition>186</StartingPosition>
                        <EndingPosition>191</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3023</LocationOfData>
                <EpitopeId>41968</EpitopeId>
                <ReferenceStartingPosition>186</ReferenceStartingPosition>
                <ReferenceEndingPosition>191</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Since C terminal pentamer sequence (MLIIWG) of peptide HA173-190 (VAKGSYNNTSGEQMLIIW) was shown previously to be the minimal epitope recognized by CTLs induced with HA173-190, but heptamers with 2 extra C ter aa (MLIIWGI or MLIIWGV) are better at sensitizing APCs, the hexamer epitope was assayed.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  1</LocationOfData>
                        <TCellId>9507</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenReferenceName>HA 186-191</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MLIIWG</LinearSequence>
                                            <StartingPosition>186</StartingPosition>
                                            <EndingPosition>191</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>NaÃÂ¯ve splenocytes from C57BL/6J mice were used to establish peptide specific CTLs  by weekly stimulation with syngeneic irradiated spleen cells pulsed with 1 μM peptide. 12 weeks of restimulation were necessary to obtain CTLs against this epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Plasma cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000639</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>128</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA186-191</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLIIWG</LinearSequence>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>191</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide is able to sensitize APCs for recognition by anti-cognate CTLs both at 1 μM and 1 nM concentration. The plasmacitoma cell line Pc11198 was used as the target cells to measure M3 restricted response since they are H2^d2 and therefore eliminate the chance for H2 or Qa1 restricted recognition and lysis by CTLs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA186-192 V</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MLIIWGV</LinearSequence>
                        <StartingPosition>186</StartingPosition>
                        <EndingPosition>192</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>387161</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 3023</LocationOfData>
                <EpitopeId>41970</EpitopeId>
                <ReferenceStartingPosition>186</ReferenceStartingPosition>
                <ReferenceEndingPosition>192</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>CTLs induced with peptide HA173-190 (VAKGSYNNTSGEQMLIIW) were shown previously to recognize a minimal epitope composed of the 5 C ter aa (MLIIW)/. In this paper, it is shown that heptamers with 2 extra C ter aa (MLIIWGI or MLIIWGV) are better at sensitizing APCs. This is a M3 restricted epitope, but its affinity for this MHC molecule is lower than that of formylated peptides.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  1</LocationOfData>
                        <TCellId>9509</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenReferenceName>HA 186-192 V</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MLIIWGV</LinearSequence>
                                            <StartingPosition>186</StartingPosition>
                                            <EndingPosition>192</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03451.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>387161</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>NaÃÂ¯ve splenocytes from C57BL/6J mice were used to establish peptide specific CTLs  by weekly stimulation with syngeneic irradiated spleen cells pulsed with 1 μM peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Plasma cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000639</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>128</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA186-192 V</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MLIIWGV</LinearSequence>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>192</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>387161</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide is able to sensitize APCs for recognition by anti-cognate CTLs both at 1 μM and 1 nM concentration. The plasmacitoma cell line Pc11198 was used as target cells to measure M3 restricted response since they are H2^d2 and therefore eliminate the chance for H2 or Qa1 restricted recognition and lysis by CTLs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure  2</LocationOfData>
                        <MhcBindingId>10480</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide was able to compete with the binding to M3 MHC molecules of formylated peptide MFFINVLTL more strongly than the pentamer WLIIW, but still requiring ~5000-fold higher concentration to inhibit 50% of binding.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>128</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA186-192 I</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>MLIIWGI</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Page 3023</LocationOfData>
                <EpitopeId>41969</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>CTLs induced with peptide HA173-190 (VAKGSYNNTSGEQMLIIW) were shown previously to recognize a minimal epitope composed of the 5 C ter aa (MLIIW). In this paper, it is shown that heptamers with 2 extra C ter aa (MLIIWGI or MLIIWGV) are better at sensitizing APCs. This epitope is an analog to peptide MLIIWGV from Influenza A/Japan/305/57, with a Ile at position 7, and it is found in some avian strains of influenza. This is a M3 restricted epitope, but its affinity for this MHC molecule is lower than that of formylated peptides. Epitope MLIIWGI is an analog of peptide MLIIWGV from the hemagglutinin protein of influenza A virus (A/duck/Hokkaido/107/01).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure  1</LocationOfData>
                        <TCellId>9511</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenReferenceName>HA 186-192 I</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>MLIIWGI</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Naive splenocytes from C57BL/6J mice were used to establish peptide specific CTLs  by weekly stimulation with syngeneic irradiated spleen cells pulsed with 1 μM peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Plasma cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000639</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>128</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Single MHC type present</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA186-192 I</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>MLIIWGI</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide is able to sensitize APCs for recognition by anti-cognate CTLs both at 1 μM and 1 nM concentration. The plasmacitoma cell line Pc11198 was used as the target cells to measure M3 restricted response since they are H2^d2 and therefore eliminate the chance for H2 or Qa1 restricted recognition and lysis by CTLs.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure  2</LocationOfData>
                        <MhcBindingId>10481</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>226</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>This peptide was able to compete with the binding to M3 MHC molecules of formylated peptide MFFINVLTL more strongly than pentamer WLIIW and heptamer MLIIWGV, but still requiring ~1000-fold higher concentration to inhibit 50% of binding.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>128</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

